her2靶向治疗胃肠道肿瘤的研究进展

Q4 Medicine
K. Sawada, Y. Nakamura, K. Shitara
{"title":"her2靶向治疗胃肠道肿瘤的研究进展","authors":"K. Sawada, Y. Nakamura, K. Shitara","doi":"10.17925/eoh.2020.16.1.29","DOIUrl":null,"url":null,"abstract":"Human epidermal growth factor receptor 2 (HER2) amplification is an important molecular mechanism underlying carcinogenesis and is associated with various types of cancer. Although the advancement of HER2-targeted therapy has been the most pronounced in breast cancer, interest has emerged in exploring the efficacy of HER2-targeted therapies in gastrointestinal (GI) cancers. In particular, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric or oesophagogastric junction cancer. Although subsequent trials involving lapatinib, ado-trastuzumab emtansine (T-DM1), and pertuzumab have failed to show significant survival benefits for HER2-positive gastric or oesophagogastric junction cancer, several trials are currently ongoing. HER2-targeted therapy has also been tested in patients with other GI cancers. Some combination therapies, such as trastuzumab plus pertuzumab, have shown promising results in single-arm phase II studies. Moreover, trials of novel anti-HER2 agents, including trastuzumab deruxtecan (T-DXd), tucatinib and margetuximab – which demonstrated improvement of clinical outcomes in breast cancer – are ongoing for GI cancers. In this review, we provide an overview of the current status of HER2-targeted therapies and focus on future perspectives for overcoming issues in the treatment of HER2-positive GI cancer.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"257 1","pages":"29"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Development ofHER2-targeted Therapies for Gastrointestinal Cancer\",\"authors\":\"K. Sawada, Y. Nakamura, K. Shitara\",\"doi\":\"10.17925/eoh.2020.16.1.29\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Human epidermal growth factor receptor 2 (HER2) amplification is an important molecular mechanism underlying carcinogenesis and is associated with various types of cancer. Although the advancement of HER2-targeted therapy has been the most pronounced in breast cancer, interest has emerged in exploring the efficacy of HER2-targeted therapies in gastrointestinal (GI) cancers. In particular, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric or oesophagogastric junction cancer. Although subsequent trials involving lapatinib, ado-trastuzumab emtansine (T-DM1), and pertuzumab have failed to show significant survival benefits for HER2-positive gastric or oesophagogastric junction cancer, several trials are currently ongoing. HER2-targeted therapy has also been tested in patients with other GI cancers. Some combination therapies, such as trastuzumab plus pertuzumab, have shown promising results in single-arm phase II studies. Moreover, trials of novel anti-HER2 agents, including trastuzumab deruxtecan (T-DXd), tucatinib and margetuximab – which demonstrated improvement of clinical outcomes in breast cancer – are ongoing for GI cancers. In this review, we provide an overview of the current status of HER2-targeted therapies and focus on future perspectives for overcoming issues in the treatment of HER2-positive GI cancer.\",\"PeriodicalId\":38554,\"journal\":{\"name\":\"European Oncology and Haematology\",\"volume\":\"257 1\",\"pages\":\"29\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Oncology and Haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/eoh.2020.16.1.29\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Oncology and Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/eoh.2020.16.1.29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

人表皮生长因子受体2 (HER2)扩增是致癌的重要分子机制,与多种类型的癌症有关。尽管her2靶向治疗在乳腺癌中的进展最为显著,但人们对探索her2靶向治疗在胃肠道(GI)癌症中的疗效也产生了兴趣。特别是,在一线化疗中加入曲妥珠单抗提高了her2阳性胃癌或食管胃结癌患者的总生存率。尽管随后涉及拉帕替尼、阿多-曲妥珠单抗emtansine (T-DM1)和帕妥珠单抗的试验未能显示出her2阳性胃癌或食管胃结癌的显著生存益处,但目前仍有几项试验正在进行中。her2靶向治疗也在其他胃肠道癌症患者中进行了测试。一些联合疗法,如曲妥珠单抗加帕妥珠单抗,在单臂II期研究中显示出有希望的结果。此外,新型抗her2药物的试验,包括曲妥珠单抗德鲁替康(T-DXd)、图卡替尼和马吉妥昔单抗——已证明改善乳腺癌的临床结果——正在进行中,用于胃肠道癌症。在这篇综述中,我们概述了her2靶向治疗的现状,并重点讨论了在治疗her2阳性胃肠道癌症中克服问题的未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development ofHER2-targeted Therapies for Gastrointestinal Cancer
Human epidermal growth factor receptor 2 (HER2) amplification is an important molecular mechanism underlying carcinogenesis and is associated with various types of cancer. Although the advancement of HER2-targeted therapy has been the most pronounced in breast cancer, interest has emerged in exploring the efficacy of HER2-targeted therapies in gastrointestinal (GI) cancers. In particular, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric or oesophagogastric junction cancer. Although subsequent trials involving lapatinib, ado-trastuzumab emtansine (T-DM1), and pertuzumab have failed to show significant survival benefits for HER2-positive gastric or oesophagogastric junction cancer, several trials are currently ongoing. HER2-targeted therapy has also been tested in patients with other GI cancers. Some combination therapies, such as trastuzumab plus pertuzumab, have shown promising results in single-arm phase II studies. Moreover, trials of novel anti-HER2 agents, including trastuzumab deruxtecan (T-DXd), tucatinib and margetuximab – which demonstrated improvement of clinical outcomes in breast cancer – are ongoing for GI cancers. In this review, we provide an overview of the current status of HER2-targeted therapies and focus on future perspectives for overcoming issues in the treatment of HER2-positive GI cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Oncology and Haematology
European Oncology and Haematology Medicine-Hematology
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信